RO 7497987
Alternative Names: RG 6392; RO-7497987Latest Information Update: 24 Aug 2023
At a glance
- Originator Roche
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 24 Aug 2023 Discontinued - Phase-I for Cancer (In volunteers) in USA (IV) (Roche pipeline, August 2023)
- 19 Jan 2023 Roche completes a phase I trial in Cancer in the USA
- 24 Jun 2021 Phase-I clinical trials in Cancer (In volunteers) in USA (IV) (ISRCTN92655801)